VTRS Live signals | Maximize Profits with Getagraph.com

SELL 1342 min ago

@ $11.25

Issued: 19 Apr 2024 @ 09:52

Return: 0.04%

Previous signal: Apr 18 - 13:54

Previous signal: Buy

Return: 1.35 %

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 16:00):

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets...

Stats
Today's Volume	4.51M
Average Volume	8.96M
Market Cap	13.36B
EPS	$0 ( 2024-02-28 )
Next earnings date	( $0 ) 2024-05-06
Last Dividend	$0.120 ( 2023-11-22 )
Next Dividend	$0 ( N/A )
P/E	225.00
ATR14	$0.210 (1.87%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-18	Le Goff Corinne	Buy	110 162	Restricted Stock Units
2024-04-18	Le Goff Corinne	Buy	78 688	Restricted Stock Units
2024-04-15	Le Goff Corinne	Buy	0
2024-04-02	Malik Rajiv	Buy	18 845	Restricted Stock Units
2024-03-13	Mauro Anthony	Sell	250 000	Common Stock

INSIDER POWER
9.39
Last 99 transactions
Buy: 1 339 847 \| Sell: 1 117 278

Volume Correlation

Long: 0.68 (moderate)

Short: 0.28 (neutral)

Signal:(52) Neutral

Viatris Inc. Correlation

10 Most Positive Correlations
MMAC	0.897
NETE	0.888
SRAC	0.833
AMRB	0.83
RAVN	0.829
BRKH	0.824
DOOO	0.824
EUSG	0.819
BOCH	0.817
TKNO	0.816

10 Most Negative Correlations
SVOK	-0.94
PAIC	-0.907
SVAC	-0.9
RMRM	-0.883
FEYE	-0.846
TLGT	-0.841
SPRT	-0.83
FTOCU	-0.823
FTOC	-0.815
OPCH	-0.808

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Viatris Inc. Correlation - Currency/Commodity

0.50
( weak )

0.41
( neutral )

0.00
( neutral )

-0.69
( moderate negative )

0.00
( neutral )

-0.25
( neutral )

Viatris Inc. Financials

Annual	2023
Revenue:	$15.38B
Gross Profit:	$6.57B (42.70 %)
EPS:	$0.0456

Q4	2023
Revenue:	$3.82B
Gross Profit:	$1.61B (42.11 %)
EPS:	$-0.640

Q3	2023
Revenue:	$3.94B
Gross Profit:	$1.69B (42.91 %)
EPS:	$0.280

Q2	2023
Revenue:	$3.92B
Gross Profit:	$1.61B (41.05 %)
EPS:	$0.220

Financial Reports:

No articles found.

Viatris Inc. Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0.120 (N/A)	$0.120 (N/A)	$0.120 (N/A)	$0.120 (N/A)	$0.240 (N/A)	$0.120 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Viatris Inc. Dividend Information - Dividend King

Dividend Sustainability Score: 6.81 - average (93.69%) | Divividend Growth Potential Score: 4.62 - Stable (7.56%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.00741	1986-12-24
Last Dividend	$0.120	2023-11-22
Next Dividend	$0	N/A
Payout Date	2023-12-15
Next Payout Date	N/A
# dividends	88	--
Total Paid Out	$2.99	--
Avg. Dividend % Per Year	2.32%	--
Score	5.02	--
Div. Sustainability Score	6.81
Div.Growth Potential Score	4.62
Div. Directional Score	5.72	--

Next Divdend (Est)
(2024-06-03)

$0.123 Estimate 35.64 %

Dividend Stability

0.71 Good

Dividend Score

5.02

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield
1986	$0.00741	0.28%
1987	$0.0148	0.88%
1988	$0.0111	0.86%
1989	$0.0148	1.13%
1990	$0.0222	0.63%
1991	$0.0296	1.01%
1992	$0.0326	0.53%
1993	$0.0416	0.46%
1994	$0.0564	0.78%
1995	$0.0652	0.85%
1996	$0.0712	0.70%
1997	$0.0712	0.97%
1998	$0.0712	0.80%
1999	$0.0712	0.53%
2000	$0.0712	0.66%
2001	$0.0712	0.65%
2002	$0.0756	0.47%
2003	$0.0966	0.61%
2004	$0.120	0.48%
2005	$0.210	1.20%
2006	$0.240	1.20%
2007	$0.120	0.60%
2008	$0	0.00%
2009	$0	0.00%
2010	$0	0.00%
2011	$0	0.00%
2012	$0	0.00%
2013	$0	0.00%
2014	$0	0.00%
2015	$0	0.00%
2016	$0	0.00%
2017	$0	0.00%
2018	$0	0.00%
2019	$0	0.00%
2020	$0	0.00%
2021	$0.330	1.78%
2022	$0.480	3.38%
2023	$0.600	5.27%
2024	$0	0.00%

Dividend Commentary

With a moderate Dividend Sustainability Score (DSS), the company may sustain its dividends, but continuous monitoring is advised for any financial shifts. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.00355	1.500	9.93	10.00	[0 - 0.5]
returnOnAssetsTTM	0.00115	1.200	9.96	10.00	[0 - 0.3]
returnOnEquityTTM	0.00263	1.500	-1.082	-1.623	[0.1 - 1]
payoutRatioTTM	10.52	-1.000	10.00	-10.00	[0 - 1]
currentRatioTTM	1.572	0.800	7.14	5.71	[1 - 3]
quickRatioTTM	0.658	0.800	-0.833	-0.666	[0.8 - 2.5]
cashRatioTTM	0.128	1.500	-0.401	-0.602	[0.2 - 2]
debtRatioTTM	0.382	-1.500	3.63	-5.45	[0 - 0.6]
interestCoverageTTM	1.886	1.000	-0.413	-0.413	[3 - 30]
operatingCashFlowPerShareTTM	2.33	2.00	9.22	10.00	[0 - 30]
freeCashFlowPerShareTTM	1.937	2.00	9.03	10.00	[0 - 20]
debtEquityRatioTTM	0.890	-1.500	6.44	-9.66	[0 - 2.5]
grossProfitMarginTTM	0.419	1.000	6.36	6.36	[0.2 - 0.8]
operatingProfitMarginTTM	0.0708	1.000	-0.585	-0.585	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.154	1.000	-0.257	-0.257	[0.2 - 2]
assetTurnoverTTM	0.323	0.800	-1.178	-0.943	[0.5 - 2]
Total Score				6.81

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	256.91	1.000	10.00	0	[1 - 100]
returnOnEquityTTM	0.00263	2.50	-0.695	-1.623	[0.1 - 1.5]
freeCashFlowPerShareTTM	1.937	2.00	9.35	10.00	[0 - 30]
dividendYielPercentageTTM	4.10	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	2.33	2.00	9.22	10.00	[0 - 30]
payoutRatioTTM	10.52	1.500	10.00	-10.00	[0 - 1]
pegRatioTTM	-1.612	1.500	-10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.182	1.000	7.96	0	[0.1 - 0.5]
Total Score				4.62

Viatris Inc.

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as offers biosimilars franchises, including Fulphila, Ogivri, Hulio, and SEMGLEE. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.